Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719801 | 0.87 | SIGMAR1 (0.66) | SIGMAR1HTR1AHTR1DHTR1BMEN1 | |
| SCHEMBL6301408 | 0.86 | HRH3 (0.59) | MEN1KMT2AHRH3 | |
| SCHEMBL14847416 | 0.85 | SIGMAR1 (0.56) | SIGMAR1HTR1AHTR1DHTR1BMEN1 | |
| SCHEMBL12879686 | 0.84 | HRH3 (0.66) | SIGMAR1MEN1KMT2AKCNH2HRH3 | |
| SCHEMBL5857315 | 0.83 | MEN1 (0.56) | SIGMAR1MEN1KMT2AKCNH2HRH3 | |
| SCHEMBL403480 | 0.82 | SIGMAR1 (0.53) | SIGMAR1HTR1AHTR1DHTR1BMEN1 | |
| SCHEMBL530072 | 0.82 | SIGMAR1 (0.70) | SIGMAR1HTR1AHTR1DHTR1BHRH3 | |
| SCHEMBL13242878 | 0.81 | SIGMAR1 (0.68) | SIGMAR1HTR1AHTR1DHTR1BHRH3 | |
| SCHEMBL13242848 | 0.79 | SIGMAR1 (0.69) | SIGMAR1HTR1AHTR1DHTR1BHRH3 | |
| SCHEMBL528725 | 0.79 | SIGMAR1 (0.69) | SIGMAR1HTR1AHTR1DHTR1BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-15 | — | — | US | disclosed |
| WO-2008055013-A2 | 5-OXO-5,8 - DIHYDRO - PYRIDO - PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | FLT3, FES, ALK | SIGMAR1 3629/4885HTR1A 1627/4885HTR1D 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.